Douglas S Goodin

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America UCSF Multiple Sclerosis Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 9:e90034. 2014
  2. ncbi request reprint Glucocorticoid treatment of multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:455-64. 2014
  3. ncbi request reprint The epidemiology of multiple sclerosis: insights to disease pathogenesis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:231-66. 2014
  4. pmc Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
    Hans Peter Hartung
    Heinrich Heine Universitat, Moorenstraße 5, Dusseldorf 40225, Germany
    J Neuroinflammation 9:129. 2012
  5. doi request reprint The use of interferon Beta and glatiramer acetate in multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, California 94143 0114, USA
    Semin Neurol 33:13-25. 2013
  6. pmc The genetic and environmental bases of complex human-disease: extending the utility of twin-studies
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e47875. 2012
  7. pmc Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
    D S Goodin
    Department of Neurology, University of California, San Francisco, CA, USA
    Neurology 78:1315-22. 2012
  8. pmc Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e22444. 2011
  9. doi request reprint Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
    Douglas S Goodin
    University of California, San Francisco, San Francisco, CA 94143 0114, USA
    J Neurol Neurosurg Psychiatry 83:282-7. 2012
  10. doi request reprint Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial
    Douglas S Goodin
    University of California at San Francisco, CA 94143 0114, USA
    Mult Scler 18:181-95. 2012

Detail Information

Publications50

  1. ncbi request reprint Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America UCSF Multiple Sclerosis Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 9:e90034. 2014
    ..However, SNPs frequently reside on several different SNP-haplotypes, only some of which may be disease-associated. This circumstance lowers the observed odds-ratio for disease-association...
  2. ncbi request reprint Glucocorticoid treatment of multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:455-64. 2014
    ....
  3. ncbi request reprint The epidemiology of multiple sclerosis: insights to disease pathogenesis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, USA Electronic address
    Handb Clin Neurol 122:231-66. 2014
    ....
  4. pmc Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
    Hans Peter Hartung
    Heinrich Heine Universitat, Moorenstraße 5, Dusseldorf 40225, Germany
    J Neuroinflammation 9:129. 2012
    ..Interferon-beta (IFNB) therapy for multiple sclerosis can lead to the induction of neutralizing antibodies (NAbs) against IFNB. Various methods are used for detection and quantification of NAbs...
  5. doi request reprint The use of interferon Beta and glatiramer acetate in multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, California 94143 0114, USA
    Semin Neurol 33:13-25. 2013
    ..Consequently, there will continue to be a place for these injectable treatments, even as we move into an era where physicians are confronted with many treatment possibilities...
  6. pmc The genetic and environmental bases of complex human-disease: extending the utility of twin-studies
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e47875. 2012
    ..Also, susceptible men (compared to susceptible women) have a lower threshold, a greater hazard-rate, or both in response to the environmental factors involved in MS pathogenesis...
  7. pmc Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial
    D S Goodin
    Department of Neurology, University of California, San Francisco, CA, USA
    Neurology 78:1315-22. 2012
    ....
  8. pmc Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e22444. 2011
    ..For example, although disease-modifying therapy in MS has a convincing benefit on several short-term outcome-measures in randomized trials, its impact on long-term function remains uncertain...
  9. doi request reprint Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
    Douglas S Goodin
    University of California, San Francisco, San Francisco, CA 94143 0114, USA
    J Neurol Neurosurg Psychiatry 83:282-7. 2012
    ..Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established...
  10. doi request reprint Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial
    Douglas S Goodin
    University of California at San Francisco, CA 94143 0114, USA
    Mult Scler 18:181-95. 2012
    ..The frequency and impact of neutralizing antibodies (NAbs) to interferon beta-1b (IFNβ-1b) on clinical and radiographic outcomes is controversial...
  11. ncbi request reprint Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis
    D S Goodin
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    J Int Med Res 35:173-87. 2007
    ..Our results suggest that NAbs are not responsible for poor clinical responses and that NAb status is of little clinical value. These findings will need to be confirmed in a large independent study...
  12. doi request reprint Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode
    D S Goodin
    Department of Neurology, University of California, San Francisco, CA 94143 0114, USA
    Mult Scler 15:1175-82. 2009
    ....
  13. pmc The genetic basis of multiple sclerosis: a model for MS susceptibility
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA, USA
    BMC Neurol 10:101. 2010
    ..MS-pathogenesis is known to involve both multiple environmental events, and several independent genetic risk-factors...
  14. pmc The causal cascade to multiple sclerosis: a model for MS pathogenesis
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 4:e4565. 2009
    ..The first acts near birth, the second acts during childhood, and the third acts long thereafter. Two candidate factors (vitamin D deficiency and Epstein-Barr viral infection) seem well suited to the first two environmental events...
  15. ncbi request reprint Multiple Sclerosis: The Big Questions- The MS Forum Workshop
    Ds Goodin
    Douglas S Goodin MS Center at the University of California San Francisco 350 Parnassus Avenue Suite 908 San Francisco CA 94117 USA Tel 415 514 2464 Fax 415 514 2470 E mail
    Int MS J 17:100-7. 2011
    ..Highlights were presentations on the controversial theory of venous obstruction as a cause of MS and updates on promising oral treatments, particularly fingolimod, cladribine and teriflumomide...
  16. ncbi request reprint Disease-modifying therapy in multiple sclerosis: update and clinical implications
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA, USA
    Neurology 71:S8-13. 2008
    ..Second, high-dose IFN beta-1a or IFN beta-1b subcutaneous has a similar clinical impact to glatiramer acetate, although IFN beta subcutaneous is superior on some MRI outcome measures...
  17. doi request reprint Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS
    A T Reder
    Department of Neurology, University of Chicago, Chicago, IL 60637, USA
    Neurology 74:1877-85. 2010
    ..The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments...
  18. pmc Switching multiple sclerosis patients with breakthrough disease to second-line therapy
    Tamara Castillo-Trivino
    Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 6:e16664. 2011
    ..The effect of natalizumab monotherapy in patients with breakthrough disease is unknown...
  19. pmc Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci
    Nikolaos A Patsopoulos
    Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Neurol 70:897-912. 2011
    ..To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci...
  20. pmc Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes
    Jeffrey M Gelfand
    University of California, San Francisco Department of Neurology, Multiple Sclerosis Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e36847. 2012
    ....
  21. ncbi request reprint Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors
    Douglas S Goodin
    Department of Neurology, Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, California 94143 0114, USA
    J Neurol 251:v3-v11. 2004
    ....
  22. pmc Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures
    E M Mowry
    Department of Neurology, University of California, San Francisco, 94117, USA
    Neurology 72:1760-5. 2009
    ..Health-related quality of life (HRQOL) is reduced in multiple sclerosis (MS). It is unclear whether HRQOL is associated with white matter lesion burden or measures of brain atrophy...
  23. ncbi request reprint Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis
    B A C Cree
    Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
    Neurology 63:2039-45. 2004
    ..African American (AA) individuals are thought to develop multiple sclerosis (MS) less frequently than Caucasian American (CA) individuals...
  24. ncbi request reprint Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome
    D T Okuda
    Department of Neurology, University of California San Francisco, UCSF Multiple Sclerosis Center, San Francisco, CA 94117, USA
    Neurology 72:800-5. 2009
    ..Routinely encountered in clinical practice, the natural history or evolution of such individuals with respect to their risk of developing multiple sclerosis (MS) is unclear...
  25. ncbi request reprint Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis
    D S Goodin
    Department of Neurology, University of California, San Francisco, Calif 94143 0114, USA
    Neuroepidemiology 18:53-63. 1999
    ..This review considers several recently published therapeutic trials in order to exemplify some of the difficulties that commonly arise in this area of clinical research...
  26. ncbi request reprint Therapeutic developments in multiple sclerosis
    D S Goodin
    Department of Neurology, M 794, University of California, San Francisco, CA 94143 0114, USA
    Expert Opin Investig Drugs 9:655-70. 2000
    ..Moreover, it also seems likely that, increasingly, therapeutic strategies that enhance or promote myelin repair will become a major focus of clinical research in this area...
  27. ncbi request reprint Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response
    D S Goodin
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    Drugs 61:1693-703. 2001
    ..As a result, it is possible that the apparent dose-response observed in these clinical trials may be due, in part, to the more frequent dose administration schedule rather than the total weekly dose...
  28. ncbi request reprint Treatment of multiple sclerosis with human beta interferon
    D S Goodin
    Department of Neurology, University of California at San Francisco, Fort Miley Veterans Administration Hospital, 94121, USA
    Int MS J 12:96-108. 2005
    ..Future therapeutic developments in MS will be fuelled by our increasing understanding of the physical and biological roles of the interferons, in health and in MS pathogenesis...
  29. ncbi request reprint Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA 94121, USA Email
    Curr Med Res Opin 23:2823-32. 2007
    ....
  30. ncbi request reprint Results of using a wireless inertial measuring system to quantify gait motions in control subjects
    Iris Tien
    Center for Information Technology Research in the Interest of Society, University of California, Berkeley, CA 94720, USA
    IEEE Trans Inf Technol Biomed 14:904-15. 2010
    ..It also presents initial results from control subjects, focusing on understanding the data recorded by the shoe-mounted sensor to quantify relevant gait-related motions...
  31. ncbi request reprint Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0114, USA
    Ann Neurol 59:597-605. 2006
    ....
  32. doi request reprint Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
    Sergio E Baranzini
    Department of Neurology, University of California, San Francisco, CA 94143 0435, USA
    Hum Mol Genet 18:767-78. 2009
    ..Gene ontology-based analysis shows a functional dichotomy between genes involved in the susceptibility pathway and those affecting the clinical phenotype...
  33. doi request reprint Electrical brain events associated with awareness of errors
    Jeffrey W Ralph
    Department of Neurology, Rm M 794, University of California, San Francisco, CA 94143 0114, USA
    Brain Res 1251:213-22. 2009
    ..The neurophysiological correlates of mental activity and awareness are important to define, as they permit the objective study of these psychological phenomena...
  34. ncbi request reprint Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response
    Douglas S Goodin
    Department of Neurology Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0114, USA
    J Neurol 251:v50-v56. 2004
    ..It is the purpose of this manuscript, therefore, to provide an overview of this process using examples from two recently completed assessments on disease-modifying therapies in multiple sclerosis...
  35. doi request reprint Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution
    Jacqueline F Marcus
    Department of Neurology, University of California, San Francisco, 350 Parnassus Ave, 908, PO Box 0114, San Francisco, CA 94143, USA
    Arch Neurol 69:129-32. 2012
    ..To describe a patient with multiple sclerosis (MS) who developed severe hypercalcemia, attributed to the additive effect of 5500 IU of cholecalciferol and 2020 mg of calcium daily...
  36. doi request reprint Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    Bruce A C Cree
    Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
    Ann Neurol 68:145-50. 2010
    ..To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients...
  37. pmc HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course
    L F Barcellos
    Department of Neurology, University of California at San Francisco, San Francisco, CA, USA
    Am J Hum Genet 72:710-6. 2003
    ..Concepts of the molecular mechanisms that underlie linkage and association of the human leukocyte antigen (HLA) region to MS need to be revised to accommodate these data...
  38. pmc Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures
    D T Okuda
    UCSF Multiple Sclerosis Center, University of California, San Francisco, San Francisco, California 94117, USA
    Brain 132:250-9. 2009
    ....
  39. pmc Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score
    Philip L De Jager
    Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet Neurol 8:1111-9. 2009
    ..We investigated the usefulness of an aggregate measure of risk of MS that is based on genetic susceptibility loci. We also assessed the added effect of environmental risk factors that are associated with susceptibility for MS...
  40. ncbi request reprint Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    D S Goodin
    University of California, San Francisco, CA, USA
    Neurology 68:977-84. 2007
    ....
  41. ncbi request reprint Neuromyelitis optica
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, USA
    Semin Neurol 22:105-22. 2002
    ..The history of NMO, its nosology, associations with other diseases, and current concepts of its pathogenesis and treatment is reviewed in this article...
  42. ncbi request reprint Long-latency cerebral event-related potentials in multiple sclerosis
    J C Aminoff
    Department of Neurology, University of California, San Francisco 94143-0114, USA
    J Clin Neurophysiol 18:372-7. 2001
    ..The recording of event-related potentials may thus provide a useful tool, not only as an objective measure of cognitive function in patients with MS, but also as an aid in the evaluation of response to treatment...
  43. ncbi request reprint Evidence-based medicine
    D S Goodin
    Department of Neurology, University of California, San Francisco, USA
    Int MS J 12:94-5. 2005
    ..Its relative objectivity means that evidence-based medicine can be a powerful tool for practising physicians. As a result, it is important for them to become familiar with this analytical method...
  44. ncbi request reprint Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre
    D S Goodin
    J Neurol 253:947-8; author reply 949. 2006
  45. ncbi request reprint Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
    D S Goodin
    Neurology 58:169-78. 2002
  46. ncbi request reprint Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial
    H Panitch
    University of Vermont College of Medicine, Burlington, VT 05401, USA
    Neurology 59:1496-506. 2002
    ..Interferon beta (IFNbeta) reduces relapses and MRI activity in relapsing-remitting MS (RRMS), with variable effects on disability. The most effective dose regimen remains controversial...
  47. ncbi request reprint The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    E M Frohman
    University of Texas Southwestern Medical Center at Dallas, USA
    Neurology 61:602-11. 2003
    ..By contrast, normal results on MRI at the time of clinical presentation makes the future development of CDMS considerably less likely...
  48. ncbi request reprint The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    D S Goodin
    Therapeutics and Technology Assessment Subcommittee, American Academy of Neurology, St Paul, MN 55116, USA
    Neurology 61:1332-8. 2003
    ....
  49. doi request reprint Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    D S Goodin
    University of California at San Francisco, USA
    Neurology 71:766-73. 2008
    ..The PML risk in a pooled clinical trial cohort has been estimated to be 1 person for every 1,000 patients treated for an average of 17.9 months, although this figure could change in either direction with more experience with the drug...